Certara (NASDAQ:CERT) Given New $12.00 Price Target at KeyCorp

Certara (NASDAQ:CERT) had its price objective boosted by KeyCorp from $9.00 to $12.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s target price would suggest a potential upside of 24.22% from the stock’s previous close.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings cut shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. UBS Group restated a “neutral” rating and issued a $10.00 price target on shares of Certara in a research report on Wednesday, September 30th. TD Cowen upped their price target on Certara from $9.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Barclays increased their price objective on Certara from $7.50 to $9.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.18.

Certara Stock Performance

Shares of CERT stock opened at $9.66 on Friday. Certara has a 12-month low of $4.45 and a 12-month high of $12.94. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -21.47 and a beta of 1.42. The business has a 50 day simple moving average of $8.52 and a 200 day simple moving average of $6.95. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55.

Certara (NASDAQ:CERT) last released its earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The company had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. During the same period in the previous year, the business posted $0.07 EPS. The firm’s quarterly revenue was down 10.8% on a year-over-year basis. On average, equities research analysts anticipate that Certara will post 0.22 EPS for the current year.

Institutional Investors Weigh In On Certara

A number of hedge funds and other institutional investors have recently made changes to their positions in CERT. GAMMA Investing LLC lifted its position in shares of Certara by 21.2% in the third quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock worth $90,000 after buying an additional 1,710 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Certara by 12.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock valued at $117,000 after acquiring an additional 1,923 shares during the last quarter. NorthRock Partners LLC bought a new position in shares of Certara in the 2nd quarter valued at approximately $68,000. Integrated Wealth Concepts LLC bought a new position in shares of Certara in the 2nd quarter valued at approximately $39,000. Finally, Corient Private Wealth LP raised its stake in shares of Certara by 166.8% in the 2nd quarter. Corient Private Wealth LP now owns 74,316 shares of the company’s stock valued at $487,000 after acquiring an additional 46,462 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.